 Drugs in Dev.
 Drugs in Dev.								 Genetic Disease
Genetic Disease
											 Undisclosed
Undisclosed
											
																			 Australia
Australia								
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinuvel Progresses Innovative DNA Repair Program
Details : Having commercialised SCENESSE® in Europe and the USA for the rare genetic disorder porphyria (EPP), CLINUVEL is expanding its clinical research, aiming to confirm how intervention with the drug enhances elimination of photoproducts and regeneration of ...
Product Name : Scenesse
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable


 
															 Reset All
Reset All